GamaMabs Pharma SA
http://www.gamamabs.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GamaMabs Pharma SA
Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
GamaMabs’ Glyco-Engineered Murlentamab Shows Promise in Colorectal, Gynecological Cancers
Murlentamab Phase II results indicate its potential for use in combination with chemotherapy or other immunological agents, to target AMHRII-expressing tumors.
Start-Up Previews, April 2014
This Month's Profile Group, Antibodies Evolve, features profiles of GamaMabs, Numab, and Zebra Biologics. Plus these Start-Ups Across Health Care: CoolCore Biomedical Technologies, EBS Technologies, and Xeltis.
GamaMabs Pharma SA
GamaMabs Pharma SA is one of the latest contenders aiming to boost the biological activity of antibodies by altering their attached sugar groups. The company, located in Toulouse, France, was founded in June 2013 to develop therapeutic antibody treatments for gynecologic cancers, using core technologies licensed from the French Laboratories for Biotechnologies.
Company Information
- Industry
- Biotechnology
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice